A tooth dentin, pulp or pulp tissue composition for treating or preventing a disease, disorder, or symptom of a tooth dentin and/or pulp or pulp tissue includes: (a) an integrin binding fragment of Laminin, the Laminin being selected from the group consisting of Laminin 511 and Laminin 411, the integrin binding fragment comprising an integrin-binding domain of the Laminin; and (b) a mixture of odontoblast and mineralized nodules secreted from the odontoblast. A coating density of the integrin binding fragment is 1 to 8 μg/cm.sup.2. The material (b) has been mixed with the material (a) in the composition so as to form pulp capping applicable to a tooth, such that the composition is able to treat or prevent the disease, disorder or symptom of the tooth dentin and/or pulp tissue including dental caries when applied to the tooth.

A tooth dentin, pulp or pulp tissue composition for treating or preventing a disease, disorder, or symptom of a tooth dentin and/or pulp or pulp tissue includes: (a) an integrin binding fragment of Laminin, the Laminin being selected from the group consisting of Laminin 511 and Laminin 411, the integrin binding fragment comprising an integrin-binding domain of the Laminin; and (b) a mixture of odontoblast and mineralized nodules secreted from the odontoblast. A coating density of the integrin binding fragment is 1 to 8 μg/cm.sup.2. The material (b) has been mixed with the material (a) in the composition so as to form pulp capping applicable to a tooth, such that the composition is able to treat or prevent the disease, disorder or symptom of the tooth dentin and/or pulp tissue including dental caries when applied to the tooth.

The present disclosure provides a bio-material composition and method of use in craniomaxillofacial surgery. An example method comprises: accessing a space defined between adjacent bone structures in a head of a patient; mixing magnesia, potassium biphosphate, and a calcium phosphate with an aqueous solution to form an activated bone fusion slurry (ABFS); applying an effective amount of the ABFS to the space between the adjacent bone structures; allowing the ABFS to set forming a bonded bone structure; and permitting bone growth into the bonded bone structure providing fusion of the two adjacent bone structures, wherein the ABFS promotes fusion of the two adjacent bone structures without the need for additional physical fixation devices.

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a vitamin for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.

A soluble zinc polyphosphate complex made by combining ingredients which include an inorganic zinc salt and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of making this soluble zinc polyphosphate.

A soluble zinc polyphosphate complex made by combining ingredients which include an inorganic zinc salt and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of making this soluble zinc polyphosphate.

A soluble zinc polyphosphate complex made by combining ingredients which include an inorganic zinc salt and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of making this soluble zinc polyphosphate.